Knockout of extended pelvic lymph node dissection during radical cystectomy
Status Publisher Language English Country Great Britain, England Media print-electronic
Document type Journal Article
PubMed
40205086
DOI
10.1038/s41585-025-01029-3
PII: 10.1038/s41585-025-01029-3
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Semmelweis University Budapest Hungary
Department of Urology University of Montreal Health Center Montreal Quebec Canada
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
See more in PubMed
Skinner, D. G. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J. Urol. 128, 34–36 (1982). PubMed DOI
Lerner, S. P. et al. Standard or extended lymphadenectomy for muscle-invasive bladder cancer. N. Engl. J. Med. 391, 1206–1216 (2024). PubMed DOI PMC
Gschwend, J. E. et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur. Urol. 75, 604–611 (2019). PubMed DOI
Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2408154 (2024). PubMed DOI
Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021). PubMed DOI PMC
Apolo, A. B. et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2401726 (2024). PubMed DOI PMC
Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875–888 (2024). PubMed DOI
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03924895 (2025).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04700124 (2024).
